drugset

drugset / Trial / NCT02571192

A Study to Investigate How the Study Drug SHP626 is Eliminated From the Body After One Dose

NCT02571192 ↗

Phase 1 Completed 8 enrolled Mirum Pharmaceuticals, Inc.

NaSingle-groupOpen-labelBasic science

Summary

The purpose of this study is to determine how SHP626 is absorbed and excreted from the body in healthy males.

Timeline

Start: 2015-10-01
Primary completion: 2015-10-01
Completion: 2015-10-01

Publications

Siebers N, Palmer M, Silberg DG, Jennings L, Bliss C, Martin PT. Absorption, Distribution, Metabolism, and Excretion of [14C]-Volixibat in Healthy Men: Phase 1 Open-Label Study. Eur J Drug Metab Pharmacokinet. 2018 Feb;43(1):91-101. doi: 10.1007/s13318-017-0429-7.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Volixibat	Small molecule	50 mg	Oral

Indications